THE Therapeutic Goods Administration has released its Australian Public Assessment Report for Roche Products' Actemra (tocilizumab) confirming approval for an extension of indications to include the treatment of giant cell arteritis in adults - access at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jun 18
